This CME program is derived from content presented at the 2022 Eastern Pulmonary Conference. The expert faculty, Dr. Gregory Tino, will first outline the pathophysiology, prevalence and radiological distribution of non-cystic fibrosis bronchiectasis (NCFBE). Current treatment guidelines and recommendations for patients with NCFBE will be reviewed and an overview of phenotyping provided. Dr. Tino will conclude with an analysis of current trial data, including a discussion of practical implications for clinicians who treat and manage patients with non-cystic fibrosis bronchiectasis.
Pulmonologists, primary care physicians, radiologists, advanced practitioners, and other healthcare professionals who care for patients with NCFBE
Understand the science of NCFBE, including disease burden, unmet needs, patient risk factors and comorbidities, and early and accurate diagnostic techniques that can reduce treatment delays
Review NCFBE pathophysiology, natural history and clinical progression
Analyze the role of neutrophilic inflammation and neutrophil serine proteases in NCFBE and review clinical trial data on dipeptidyl peptidase 1 (DPP1) therapeutics.
Scientific Review of NCFBE, Including Disease Burden and Diagnostic Techniques
Review of NCFBE Pathophysiology, Natural History and Clinical Progression
Clinical Trial Review of Dipeptidyl Peptidase 1 (DPP1) Therapeutics for the Treatment of NCFBE
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Sidney S. Braman, MD | Nothing to disclose |
| Gregory Tino, MD | Consultant/Advisor: AstraZeneca; Insmed |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits TM.
Clinicians should only claim credit commensurate with the extent of their participation.
This activity has been supported by an independent educational grant from Insmed.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Insmed do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606